Rhythm Pharma's Setmelanotide Phase 3 EMANATE Trial Misses Primary Endpoints, Post Hoc Data Shows Promise
RYTM sits 87% above its 52-week low of $45.905.
Summary
Rhythm Pharmaceuticals announced that its Phase 3 EMANATE trial for setmelanotide failed to meet its primary endpoints across four substudies, though post hoc analyses revealed statistically significant BMI reductions in two specific patient populations.
Key Events · Product Development and Regulatory · RYTM
-
Phase 3 EMANATE Trial Misses Primary Endpoints
Setmelanotide failed to meet its primary endpoints across all four substudies (POMC/PCSK1 Hets, LEPR Hets, SRC1 (NCOA1), and SH2B1) in the global Phase 3 EMANATE trial.
-
Post Hoc Analyses Show Positive Signals
Despite the primary endpoint miss, post hoc analyses demonstrated statistically significant and clinically meaningful BMI reductions in POMC/PCSK1 Hets and SRC1 (NCOA1) patient populations.
-
No New Safety Concerns
The safety profile of setmelanotide in the EMANATE trial was consistent with prior studies, with no new safety signals observed.
-
Future Development Strategy
Rhythm plans to continue analyzing the EMANATE data and evaluate clinical development paths for SRC1 (NCOA1) and POMC with its next-generation MC4R agonists, bivamelagon and RM-718.
Analysis · RYTM · Life Sciences
The failure of setmelanotide to meet primary endpoints in the EMANATE Phase 3 trial is a significant setback for Rhythm Pharmaceuticals, impacting the potential expansion of the drug's label into broader genetically-driven obesity indications. While the post hoc analyses showing statistically significant BMI reductions in POMC/PCSK1 Hets and SRC1 (NCOA1) substudies offer a potential path forward for future development, particularly with next-generation MC4R agonists, the immediate market reaction is likely to be negative due to the primary endpoint miss. Investors will closely monitor the company's detailed plans for these next-generation assets and how these learnings will be integrated into their clinical strategy. The conference call today will be crucial for understanding management's perspective and future direction.
At the time of this filing, RYTM was trading at $86.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $45.91 to $122.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.